BioMarin Pharmaceutical Inc. (BMRN) Stock Price & How to Invest

BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases, a niche where it has decades of experience. Its commercial base includes enzyme replacement therapies (Vimizim, Naglazyme, Palynziq and others) for lysosomal and metabolic disorders, plus Voxzogo, an injectable for children with achondroplasia that has become the company's fastest-growing product. In April 2026 BioMarin closed its roughly $4.8 billion all-cash acquisition of Amicus Therapeutics, adding Galafold for Fabry disease and the Pombiliti plus Opfolda regimen for Pompe disease to the portfolio. Separately, the company decided to withdraw its Roctavian hemophilia gene therapy from the market after failing to find a buyer, taking an asset write-down.

The investment picture is one of steady, high-margin growth from a diversified set of rare-disease franchises rather than a single blockbuster bet. BioMarin generated about $3.2 billion of revenue in 2025 and has guided 2026 revenue to roughly $3.83 to $3.93 billion, an acceleration driven largely by the Amicus products and continued Voxzogo uptake. The bull case is durable pricing power, orphan-drug exclusivity, and Voxzogo label expansion; the bear case is heavy reliance on a few products, integration risk from the Amicus deal, and a valuation that already prices in growth.

Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. Rare-disease pricing draws scrutiny from payers and governments, and much of Voxzogo's revenue comes from international markets subject to reimbursement pressure. Competition is emerging, including Ascendis Pharma's TransCon CNP in achondroplasia and multiple Fabry and Pompe therapies from larger rivals. The Amicus acquisition adds integration and execution risk, and the Roctavian withdrawal shows that expensive programs can fail commercially. The shares trade at a premium multiple, leaving little margin for disappointment.

25 analysts publish price targets on BMRN, averaging $87.92 against a $60.02 price as of August 2026, or +46.5%. The published targets run from $50.00 to $120.00, a wide spread, and the ratings split 19 buy, 6 hold, 0 sell. Over the last six months there have been 3 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BMRN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on BioMarin Pharmaceutical Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Voxzogo growth engine. Voxzogo, for children with achondroplasia, generated roughly $920 million in 2025 and remains the primary growth driver, with most sales coming from outside the United States. The most optimistic published target, $120.00, assumes this works close to its best case.

The case against. Revenue is concentrated in a handful of products, so a setback for Voxzogo or a key enzyme therapy would weigh heavily on results. The most pessimistic target, $50.00, is roughly what BMRN is worth if this bites instead.

Read the full bull and bear case on BMRN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see BioMarin Pharmaceutical Inc.'s investor relations page or your broker.

• Revenue (2025): ~$3.2B
• 2026 revenue guidance: ~$3.83B to $3.93B
• Q1 2026 revenue: ~$766M
• Q1 2026 non-GAAP EPS: ~$0.76
• 2026 non-GAAP EPS guidance: ~$4.85 to $5.05
• Market cap: ~$11B

BioMarin posted record 2025 revenue of about $3.2 billion and raised its 2026 revenue guidance to roughly $3.83 to $3.93 billion after adding the Amicus products, implying around 20 percent growth at the midpoint. Non-GAAP EPS guidance for 2026 was trimmed slightly to about $4.85 to $5.05 to reflect near-term dilution from the acquisition. Reported trailing GAAP multiples look elevated versus biotech peers, so the story depends on the guided growth materializing.

These are the investment theses BMRN naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to BMRN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get BMRN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BMRN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BMRN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

BMRN is a profitable, growing rare-disease specialist whose value rests on Voxzogo momentum and successful Amicus integration, offset by pipeline and pricing risk.

Whether BMRN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BMRN a buy or a sell?, and where the stock could go from here in the BMRN stock forecast.

For income investors, whether BMRN pays a dividend and how the payout looks is covered in does BMRN pay a dividend? And to weigh BMRN against a peer, read the full side-by-side comparisons: BMRN vs VRTX and BMRN vs REGN.